Want to see CRVS full AI Analyst Report?
Total Valuation
Corvus Pharmaceuticals has a market cap or net worth of $1.26B. The enterprise value is $969.82M.
Market Cap$1.26B
Enterprise Value$969.82M
Share Statistics
Corvus Pharmaceuticals has 84,090,420 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding84,090,420
Owned by Insiders22.36%
Owned by Institutions45.57%
Financial Efficiency
Corvus Pharmaceuticals’s return on equity (ROE) is -0.25 and return on invested capital (ROIC) is -69.15%.
Return on Equity (ROE)-0.25
Return on Assets (ROA)-0.21
Return on Invested Capital (ROIC)-69.15%
Return on Capital Employed (ROCE)-0.70
Revenue Per Employee0.00
Profits Per Employee-493.00K
Employee Count31
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Corvus Pharmaceuticals is ―. Corvus Pharmaceuticals’s PEG ratio is 0.50.
PE Ratio―
PS Ratio0.00
PB Ratio9.93
Price to Fair Value9.93
Price to FCF-18.44
Price to Operating Cash Flow-38.42
PEG Ratio0.50
Income Statement
In the last 12 months, Corvus Pharmaceuticals had revenue of 0.00 and earned -15.28M in profits. Earnings per share was -0.19.
Revenue0.00
Gross Profit-105.00K
Operating Income-42.97M
Pretax Income-15.28M
Net Income-15.28M
EBITDA-15.18M
Earnings Per Share (EPS)-0.19
Cash Flow
In the last 12 months, operating cash flow was -34.91M and capital expenditures -229.00K, giving a free cash flow of -35.14M billion.
Operating Cash Flow-34.91M
Free Cash Flow-35.14M
Free Cash Flow per Share-0.42
Dividends & Yields
Corvus Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.92
52-Week Price Change287.05%
50-Day Moving Average13.63
200-Day Moving Average12.02
Relative Strength Index (RSI)60.60
Average Volume (3m)1.69M
Important Dates
Corvus Pharmaceuticals upcoming earnings date is Aug 11, 2026, TBA (Confirmed).
Last Earnings DateMay 7, 2026
Next Earnings DateAug 11, 2026
Ex-Dividend Date―
Financial Position
Corvus Pharmaceuticals as a current ratio of 6.21, with Debt / Equity ratio of 0.35%
Current Ratio6.21
Quick Ratio6.21
Debt to Market Cap<0.01
Net Debt to EBITDA0.24
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Corvus Pharmaceuticals has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Corvus Pharmaceuticals EV to EBITDA ratio is -39.82, with an EV/FCF ratio of -18.33.
EV to Sales0.00
EV to EBITDA-39.82
EV to Free Cash Flow-18.33
EV to Operating Cash Flow-18.43
Balance Sheet
Corvus Pharmaceuticals has $236.71M in cash and marketable securities with $834.00K in debt, giving a net cash position of $235.88M billion.
Cash & Marketable Securities$236.71M
Total Debt$834.00K
Net Cash$235.88M
Net Cash Per Share$2.81
Tangible Book Value Per Share$0.78
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Corvus Pharmaceuticals is $31.60, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$31.60
Price Target Upside88.77% Upside
Analyst ConsensusStrong Buy
Analyst Count5
Revenue Growth Forecast―
EPS Growth Forecast17.91%